109 research outputs found

    Alkaline phosphatase binds tenaciously to titanium; implications for biological surface evaluation following bone implant retrieval

    Get PDF
    © 2017 Elsevier B.V. Enhancing the performance and longevity of titanium (Ti) implants continues to be a significant developmental theme in contemporary biomaterials design. Our specific focus pertains to the surface functionalisation of Ti using the bioactive lipid, lysophosphatidic acid (LPA) and certain phosphatase-resistant analogues of LPA. Coating survivorship to a plethora of testing regimens is required to align with due regulatory process before novel biomaterials can enter clinical trials. One of the key acceptance criteria is coating retention to the physical stresses experienced during implantation. In assessing coating stability to insertion into porcine bone we found that a subsequent in vitro assessment to confirm coating persistence was masked by abundant alkaline phosphatase (ALP) contamination adsorbed to the metal surface. Herein we report that ALP can bind to Ti in a matter of minutes by simply immersing Ti samples in aqueous solutions of the enzyme. We strongly discourage the in vitro monitoring of osteoblast and stromal cell ALP expression when assessing bioactive coating survivorship following Ti implant retrieval form native bone tissue

    A Blockchain-Based Audit Trail Mechanism: Design and Implementation

    Get PDF
    Audit logs are a critical component in today’s enterprise business systems as they provide several benefits such as records transparency and integrity and security of sensitive information by creating a layer of evidential support. However, current implementations are vulnerable to attacks on data integrity or availability. This paper presents a Blockchain-based audit trail mechanism that leverages the security features of Blockchain to enable secure and reliable audit trails and to address the aforementioned vulnerabilities. The architecture design and specific implementation are described in detail, resulting in a real prototype of a reliable, secure, and user-friendly audit trail mechanism.This research was funded by the European Commission, grant number 872570 (H2020 KYKLOS 4.0 project)

    Human osteoblast growth and maturation in response to metformin and the thienopyridone, A769662

    Get PDF
    Metformin (Met) is a biguanide drug widely used in the treatment and management of non insulin-dependent diabetes mellitus. In recent years it has emerged that Met, by stimulating adenosine monophosphate-activated protein kinase (AMPK), can promote the maturation of osteoblasts, albeit cells sourced from rodent and murine calvaria. Finding novel uses for existing drugs is especially appealing, primarily from the fiscal and time constraints posed in developing new products. Identifying agents capable of supporting human osteoblast growth and differentiation are attractive in a bone regenerative context. Since studies using Met are invariably restricted to rodent and murine osteoblasts we sought to investigate whether this biguanide might have a positive influence upon human osteoblast growth and maturation. To this end we examined the effect of Met on two osteoblast-like cell lines, MG63 and Saos-2, and compared the responses to primary human osteoblasts and their bone marrow-derived stem cell progeny. Furthermore we examined the effect of a cell permeable Met surrogate, A769662, which is a potent and far more selective activator of AMPK. Herein we report that Met is without influence on cell growth. Furthermore the application of Met, albeit in the millimolar range, actually inhibited osteoblast maturation. Conversely A769662 was toxic to the osteosarcoma-derived cell lines, MG63 and Saos-2, but without effect on the growth of primary cells or their stem cell progenitors. Since the cell lines are known to be p53 deficient we propose that activation of AMPK by A769662 could form part of the arsenal in the fight against osteosarcoma

    An N-cyanoamide derivative of lithocholic acid co-operates with lysophosphatidic acid to promote human osteoblast (MG63) differentiation

    Get PDF
    Less-calcaemic vitamin D receptor (VDR) agonists have the potential to promote osteoblast maturation in a bone regenerative setting. The emergence of lithocholic acid (LCA) as a bona fide VDR agonist holds promise as an adjunct for arthroplasty following reports that it was less calcaemic than calcitriol (1,25D). However, LCA and some earlier derivatives, e.g., LCA acetate, had to be used at much higher concentrations than 1,25D to elicit comparable effects on osteoblasts. However, recent developments have led to the generation of far more potent LCA derivatives that even outperform the efficacy of 1,25D. These new compounds include the cyanoamide derivative, Dcha-150 (also known as AY2-79). In light of this significant development, we sought to ascertain the ability of Dcha-150 to promote human osteoblast maturation by monitoring alkaline phosphatase (ALP) and osteocalcin (OC) expression. The treatment of MG63 cells with Dcha-150 led to the production of OC. When Dcha-150 was co-administered with lysophosphatidic acid (LPA) or an LPA analogue, a synergistic increase in ALP activity occurred, with Dcha-150 showing greater potency compared to 1,25D. We also provide evidence that this synergy is likely attributed to the actions of myocardin-related transcription factor (MRTF)–serum response factor (SRF) gene transcription following LPA-receptor-induced cytoskeletal reorganisation

    Polydopamine-lysophosphatidate-functionalised titanium: A novel hybrid surface finish for bone regenerative applications

    Get PDF
    © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Aseptic loosening of total joint replacements (TJRs) continues to be the main cause of implant failures. The socioeconomic impact of surgical revisions is hugely significant; in the United Kingdom alone, it is estimated that £135m is spent annually on revision arthroplasties. Enhancing the longevity of titanium implants will help reduce the incidence and overall cost of failed devices. In realising the development of a superior titanium (Ti) technology, we took inspiration from the growing interest in reactive polydopamine thin films for biomaterial surface functionalisations. Adopting a “one-pot” approach, we exposed medical-grade titanium to a mildly alkaline solution of dopamine hydrochloride (DHC) supplemented with (3S)1-fluoro-3-hydroxy-4-(oleoyloxy)butyl-1-phosphonate (FHBP), a phosphatase-resistant analogue of lysophosphatidic acid (LPA). Importantly, LPA and selected LPA analogues like FHBP synergistically cooperate with calcitriol to promote human osteoblast formation and maturation. Herein, we provide evidence that simply immersing Ti in aqueous solutions of DHC-FHBP afforded a surface that was superior to FHBP-Ti at enhancing osteoblast maturation. The facile step we have taken to modify Ti and the biological performance of the final surface finish are appealing properties that may attract the attention of implant manufacturers in the future

    Development and biological evaluation of fluorophosphonate-modified hydroxyapatite for orthopaedic applications

    Get PDF
    There is an incentive to functionalise hydroxyapatite (HA) for orthopaedic implant use with bioactive agents to encourage superior integration of the implants into host bone. One such agent is (3S) 1-fluoro-3-hydroxy-4-(oleoyloxy) butyl-1-phosphonate (FHBP), a phosphatase-resistant lysophosphatidic acid (LPA) analogue. We investigated the effect of an FHBP-HA coating on the maturation of human (MG63) osteoblast-like cells. Optimal coating conditions were identified and cell maturation on modified and unmodified, control HA surfaces was assessed. Stress tests were performed to evaluate coating survivorship after exposure to mechanical and thermal insults that are routinely encountered in the clinical environment. MG63 maturation was found to be three times greater on FHBP-modified HA compared to controls (p < 0.0001). There was no significant loss of coating bioactivity after autoclaving (P = 0.9813) although functionality declined by 67% after mechanical cleaning and reuse (p < 0.0001). The bioactivity of modified disks was significantly greater than that of controls following storage for up to six months (p < 0.001). Herein we demonstrate that HA can be functionalised with FHBP in a facile, scalable manner and that this novel surface has the capacity to enhance osteoblast maturation. Improving the biological performance of HA in a bone regenerative setting could be realised through the simple conjugation of bioactive LPA species in the future. Depicted is a stylised summary of hydroxyapatite (HA) surface modification using an analogue of lysophosphatidic acid, FHBP. a HA surfaces are simply steeped in an aqueous solution of 2 μM FHBP. b The polar head group of some FHBP molecules react with available hydroxyl residues at the mineral surfaces forming robust HA-O-P bonds leaving acyl chain extensions perpendicular to the HA surface. These fatty acyl chains provide points of integration for other FHBP molecules to facilitate their self-assembly. This final surface finish enhanced the human osteoblast maturation response to calcitriol, the active vitamin D3 metabolite

    Uranium(III) coordination chemistry and oxidation in a flexible small-cavity macrocycle

    Get PDF
    U(III) complexes of the conformationally flexible, small-cavity macrocycle trans-calix[2]benzene[2]pyrrolide (L)2–, [U(L)X] (X = O-2,6-tBu2C6H3, N(SiMe3)2), have been synthesized from [U(L)BH4] and structurally characterized. These complexes show binding of the U(III) center in the bis(arene) pocket of the macrocycle, which flexes to accommodate the increase in the steric bulk of X, resulting in long U–X bonds to the ancillary ligands. Oxidation to the cationic U(IV) complex [U(L)X][B(C6F5)4] (X = BH4) results in ligand rearrangement to bind the smaller, harder cation in the bis(pyrrolide) pocket, in a conformation that has not been previously observed for (L)2–, with X located between the two ligand arene rings
    corecore